Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
Yamagata
Michiko
M
Murohisa
Toshimitsu
T
Tsuchida
Kohei
K
Okamoto
Yutaka
Y
Tsunoda
Saburo
S
Nakamura
Masae
M
Kusano
Koji
K
Majima
Yuichi
Y
Kuniyoshi
Toru
T
Iijima
Makoto
M
Sugaya
Hitoshi
H
Hiraishi
Hideyuki
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood / Q000235:genetics*; D004317:Doxorubicin / Q000627:therapeutic use; D006509:Hepatitis B / Q000097:blood / Q000209:etiology* / Q000235:genetics; D006515:Hepatitis B virus / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D016393:Lymphoma, B-Cell / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D004279:DNA, Viral; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone